Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Celgene Corporation (CELG - Analyst Report) recently inked a deal with German company MorphoSys to co-develop oncology candidate MOR202 on a global basis for treating patients with multiple myeloma and certain cancer forms. As per deal, the companies have also agreed to co-promote MOR202 in Europe for the above indications.

Celgene and MorphoSys will share the costs for developing the candidate on a 1/3:2/3 basis. MOR202, a human monoclonal antibody, is currently being evaluated in a phase I/IIa study for treating patients suffering from relapsed/refractory myeloma. The deal is worth up to $818 million, assuming all milestones are achieved.  

As per the terms of the deal, Celgene will make an upfront license payment of $92 million to the German company. Furthermore, the US based biopharmaceutical company will invest $60 million in order to subscribe the new shares of MorphoSys. The new shares will be issued at the price determined once the deal becomes effective. The companies said that the deal will become effective as soon as it is cleared by the antitrust authorities in the US under the Hart-Scott-Rodino Act. As per the deal, the price will include at least a 15% premium to MorphoSys’ closing price (prior to the deal being inked). This will benefit the shareholders of MorphoSys.

Moreover, MorphoSys is eligible to milestone payments from Celgene apart from tiered double-digit royalties on net sales of MOR202 (on approval) in markets outside Europe. The profits emanating from sales in the markets, where the companies will co-promote MOR202, will be shared equally.

We believe that the deal is also beneficial for Celgene which already has a strong oncology pipeline/product portfolio. Successful development and subsequent commercialization of MOR202 will further boost the company’s oncology portfolio.

Celgene carries a Zacks Rank #3 (Hold). Companies such as Biogen Idec Inc. (BIIB - Analyst Report), Jazz Pharmaceuticals Public Limited Company (JAZZ - Analyst Report) and Alnylam Pharmaceuticals, Inc. (ALNY - Analyst Report) appear to be more attractive. While Alnylam Pharma carries a Zacks Rank #2 (Buy), Biogen Idec and Jazz Pharma carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +6.05%
QUESTCOR PHA QCOR 80.07 +2.47%
VIPSHOP HOLD VIPS 156.35 +1.82%
ENLINK MIDST ENLC 36.29 +1.60%
BNC BANCORP BNCN 17.33 +1.58%